This observational, multicentre study showed that patients with premorbid GLP1-RA or SGLT2i prescribing had lower mortality rates and other adverse clinical outcomes (total mortality, emergency room visits, hospitalization, and mechanical ventilation within 14 days of COVID-19 diagnosis) as compared with DPP4i prescribing, as seen in Table 1. This evidence concerns the gene GLP1R and COVID-19.